Half-year report · HY
6523.TEDINET S100X235
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥173.4bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥361.6bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥173.9bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥10.4bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥941m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥18.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥559m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥10.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥692m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥4.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥525.8bn | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥532.5bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥525.4bn | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥379.8bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥391.3bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥146.0bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥141.2bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥127.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥146.7bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥141.6bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥127.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥33.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥39.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥33.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥12.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥41.9bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥13.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥17.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥20.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-4.42 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥83.13 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥32.52 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-4.42 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥82.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥32.42 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 27.9% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 26.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.3% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | ¥2.9bn |
| Reconciling Itemsreconciling | revenue external | 2025-04-01 → 2025-09-30 | ¥2.9bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥3.2bn |
| Diabetes Managementreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥48.7bn |
| Diabetes Managementreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥48.7bn |
| Diabetes Managementreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥9.3bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥59.1bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥59.1bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Healthcare Solutionsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥62.7bn |
| Healthcare Solutionsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥62.7bn |
| Healthcare Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥170.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥170.5bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥13.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.3bn |
| Diabetes Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| Diabetes Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| Diabetes Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.4bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Healthcare Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| Healthcare Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| Healthcare Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 753
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 21870000 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.1729 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 12297000 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0972 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 9766000 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0772 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 5714000 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0452 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 4250000 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0336 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 1172000 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0093 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 900000 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0071 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 630000 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0050 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 527000 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0042 | |
| Number of shares held | InterimInstant | 105124000 | |
| Shareholding ratio | InterimInstant | 0.8314 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 211900 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 126435800 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 1264358 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 74120 | |
| Number of shares issued shares voting rights | InterimInstant | 126721820 | |
| Number of voting rights issued shares voting rights | InterimInstant | 1264358 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 211900 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 211900 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.0017 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 211900 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 211900 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.0017 | |
| Cash and cash equivalents IFRS | Prior1YearInstant | 39592000000 | JPY |
| Cash and cash equivalents IFRS | InterimInstant | 33309000000 | JPY |
| Trade receivables ca IFRS | Prior1YearInstant | 70530000000 | JPY |
| Trade receivables ca IFRS | InterimInstant | 65370000000 | JPY |
| Inventories ca IFRS | Prior1YearInstant | 51694000000 | JPY |
| Inventories ca IFRS | InterimInstant | 57897000000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 4308000000 | JPY |
| Other financial assets ca IFRS | InterimInstant | 3544000000 | JPY |
| Other current assets ca IFRS | Prior1YearInstant | 6665000000 | JPY |
| Other current assets ca IFRS | InterimInstant | 8935000000 | JPY |
| Current assets IFRS | Prior1YearInstant | 172790000000 | JPY |
| Current assets IFRS | InterimInstant | 169056000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |